Actively Recruiting
Evaluating Lusutrombopag for Safety and Effectiveness After Stem Cell Transplant in Patients with Blood Disorders
Led by The General Hospital of Western Theater Command · Updated on 2026-03-25
45
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the clinical effectiveness and safety of Lusutrombopag in helping platelet recovery after allogeneic hematopoietic stem cell transplantation in patients with blood disorders. This is a prospective, single-center, open-label clinical trial led by The General Hospital of Western Theater Command. The study focuses on patients undergoing transplantation and aims to assess platelet remodeling and engraftment rates. Participants will receive Lusutrombopag starting at 3 mg once daily. Treatment lasts for up to two weeks until complete response is achieved, discontinued after 14 days of continuous therapy, or if certain stopping criteria are met. After this treatment period plus an additional 14 days, patients will be monitored to determine if ongoing medication or changes in regimen are needed. During the study, researchers will track the platelet accumulation engraftment rate 21 days after transplantation as the primary outcome. Secondary outcomes include measuring the median time to platelet and neutrophil engraftment within 30 days post-transplant. Participants will be regularly assessed for clinical efficacy and safety outcomes throughout and after the treatment period. The total duration includes treatment, observation, and follow-up to ensure comprehensive monitoring of patient responses.
CONDITIONS
Brief Title
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
Research Team
L
Lei Ma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here